| 1 |
34719869 | Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA. | 2022 Mar |
3 |
| 2 |
33406639 | Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. | 2021 Jan 4 |
1 |
| 3 |
29441489 | Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway. | 2018 Sep |
1 |
| 4 |
26593250 | Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. | 2016 Jan 12 |
1 |
| 5 |
26743692 | TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition. | 2016 |
1 |
| 6 |
25565020 | Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma. | 2015 |
6 |
| 7 |
25661379 | Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species. | 2015 Feb |
2 |
| 8 |
25766331 | NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. | 2015 Mar 12 |
1 |
| 9 |
25895124 | Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. | 2015 Apr 20 |
1 |
| 10 |
26431276 | Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk. | 2015 Oct 20 |
1 |
| 11 |
26494122 | Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. | 2015 Dec 15 |
1 |
| 12 |
24481412 | IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. | 2014 Apr |
1 |
| 13 |
24908318 | Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages. | 2014 |
2 |
| 14 |
25089799 | Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma. | 2014 Nov |
2 |
| 15 |
23276925 | BlyS: a potential hallmark of multiple myeloma. | 2013 Jan 1 |
1 |
| 16 |
23894194 | Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. | 2013 Sep 1 |
3 |
| 17 |
22819259 | Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. | 2012 Oct |
3 |
| 18 |
23048077 | Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. | 2012 Dec 15 |
1 |
| 19 |
21220502 | Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. | 2011 Jan |
3 |
| 20 |
21729550 | [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism]. | 2011 Jun |
1 |
| 21 |
20335171 | Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. | 2010 May 21 |
1 |
| 22 |
20651335 | Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. | 2010 Jun |
1 |
| 23 |
20046572 | Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. | 2009 Jan-Feb |
1 |
| 24 |
18593997 | Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. | 2008 Jul 1 |
2 |
| 25 |
18776064 | Bortezomib-induced survival signals and genes in human proximal tubular cells. | 2008 Dec |
1 |
| 26 |
17237265 | Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. | 2007 Jan |
1 |
| 27 |
15210859 | Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. | 2004 Jun |
2 |